The mission of the Southwest Oncology Group (SWOG) is to conduct clinical trials to prevent and treat cancer in adults, and to improve the quality of life for cancer survivors. The mission is accomplished through the mutual efforts ofthe Group Chair's Office, the Operations Office, the Statistical Center and the dedicated oncology professionals in the institutions of the Group. The Statistical Center contributes to the mission of the Group though the following key activities: 1) Participation in protocol development, emphasizing statistically sound study designs;2) Collection, review, manage and store data from Group studies, and to follow sound quality control procedures which ensure the integrity of data evaluations;3) Development and maintenance of electronic applications to support the research and goals of the Southwest Oncology Group, including data collection, data management, data retrieval and analysis;4) Analysis, interpretation and publication of results from ail Southwest Oncology Group studies;5) Performance of methodologic research to address ongoing design and analysis issues important to the conduct of cancer clinical trials and to ancillary biologic studies;6) Participation in training of new Clinical Research Associates (CRAs) and of Young Investigators in the Group. Biostatisticians and Data Coordinators educate investigators, nurse oncologists and CRAs in statistical analysis, research design and the utilization of the most advanced scientific and data management strategies;and 7) Collaboration with the Group Chair and other investigators in the Group to improve the quality of clinical trials through the use of improved data collection forms, reproducible data definitions and economical data flow, and efficient use of Statistical Center resources.

Public Health Relevance

Clinical trials are the best mechanism for improving the outcomes of therapy for cancer, increasing the chance for cure and the probability that future patients will be given appropriate care. The SWOG Statistical Center contributes to this process through the efficient and high-quality design, management, and analysis of these trials, thereby helping to ensure that the results of clinical trials are generalizable and reproducible.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA038926-27
Application #
8213593
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
1985-01-01
Project End
2015-12-31
Budget Start
2012-01-01
Budget End
2012-12-31
Support Year
27
Fiscal Year
2012
Total Cost
$4,606,727
Indirect Cost
$1,562,329
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Lara Jr, Primo N; Moon, James; Redman, Mary W et al. (2016) Disease Control Rate at 8 Weeks Predicts Subsequent Survival in Platinum-Treated Extensive Stage Small-Cell Lung Cancer: Results From the Southwest Oncology Group (SWOG) Database. Clin Lung Cancer 17:113-8.e1-2
Othus, M; Mukherjee, S; Sekeres, M A et al. (2016) Prediction of CR following a second course of '7+3' in patients with newly diagnosed acute myeloid leukemia not in CR after a first course. Leukemia 30:1779-80
Wozniak, Antoinette J; Moon, James; Thomas Jr, Charles R et al. (2015) A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Combination of Bevacizumab (NSC-704865) in Patients With Inoperable Locally Advanced Stage III Non-Small-Cell Lung Cancer: SWOG S0533. Clin Lung Cancer 16:340-7
Mir, Muhammad A; Maurer, Matthew J; Ziesmer, Steven C et al. (2015) Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma. Blood 125:992-8
Othus, Megan; Appelbaum, Frederick R; Petersdorf, Stephen H et al. (2015) Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy. Biol Blood Marrow Transplant 21:559-64
Walter, R B; Othus, M; Burnett, A K et al. (2015) Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center. Leukemia 29:312-20
Blumenthal, Deborah T; Rankin, Cathryn; Stelzer, Keith J et al. (2015) A Phase III study of radiation therapy (RT) and O⁶-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. Int J Clin Oncol 20:650-8
Persky, Daniel O; Miller, Thomas P; Unger, Joseph M et al. (2015) Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313. Blood 125:236-41
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Ou, Sai-Hong Ignatius; Moon, James; Garland, Linda L et al. (2015) SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM). J Thorac Oncol 10:387-91

Showing the most recent 10 out of 506 publications